通过WGCNA和多种机器学习技术,采矿阶段分离相关的子宫内膜异位症诊断生物标志物:一个回顾性和名ogram研究
Qiuyi Liang1, Shengmei Yang2, Meiyi Mai1
1Computational Medicine and Epidemiology Laboratory (CMEL), The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, China.
Journal of assisted reproduction and genetics
|March 8, 2024
概括
这项研究探讨了子宫内膜异位症 (EMS) 发育中的相隔相关基因,确定了潜在的诊断生物标志物. 研究结果表明,这些基因和免疫细胞的变化对于EMs的发病和诊断至关重要.
科学领域:
- 基因组学就是基因组学.
- 分子生物学分子生物学
- 生殖医学 生殖医学
背景情况:
- 子宫内膜异位症 (EMs) 是一种复杂的妇科疾病,其病因不明.
- 识别遗传因素和可靠的生物标志物对于早期诊断和治疗EMS至关重要.
研究的目的:
- 研究相分离相关基因在子宫内膜异位症发育中的作用.
- 使用计算方法识别子宫内膜异位症的潜在诊断生物标志物.
主要方法:
- 利用权重基因同表达网络分析 (WGCNA) 和机器学习在GEO数据库数据上.
- 分析了74名子宫内膜异位症患者和74名对照组的基因表达数据.
- 进行基因组丰富分析 (GSEA) 以确定相关的生物途径.
主要成果:
- 确定了参与子宫内膜异位症发病的9个关键基因.
- 发现了用于子宫内膜异位症诊断的5个特征基因 (FOS,CFD,CCNA1,CA4,CST1).
- 在患者和对照组之间观察到免疫细胞比例 (例如T细胞,巨细胞) 的显著差异.
结论:
- 与相分离相关的基因可能参与子宫内膜异位症的发病.
- 已识别的基因和免疫细胞变异为子宫内膜异位症提供了有前途的诊断生物标志物.
- 这些发现为治疗子宫内膜异位症的新治疗策略铺平了道路.
更多相关视频
相关概念视频
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


